Although no prospective study on clinical outcome exists for the activity of checkpoint inhibitors after IL-2, retrospective observations suggest a higher than anticipated response to anti-PD-1 following IL-2.25 In this report, 18% of patients achieved partial regressions of melanoma after their high-dose IL-2 regimen. The gene discussed is IL2; the disease is melanoma.